Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials

By sjmartinez • February 11, 2023

Langley RG, Sofen H, Dei-Cas I, Reich K, Sigurgeirsson B, Warren RB, Paul C, Szepietowski JC, Tsai TF, Hampele I, You R, Charef P, Papavassilis C. Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials. Br J Dermatol. 2023 Feb 10;188(2):198-207. doi: 10.1093/bjd/ljac040. PMID: 36763857.

Tags: Dermatology, Publications

Trends in MD-PhD representation and match outcomes across competitive specialties, 2007-2024

Zhou AE, Klufas T, Choi E, Kim YW, Kim JJ, Sarfo A, Sloan B, Feng H. Trends in MD-PhD representation and match outcomes across competitive[...]

Ethical Considerations of Cosmetic GLP-1 Receptor Agonist Prescribing in Dermatology

Jonnalagadda A, Lowry WP, Pathak GN, Choi E, Zhou AE, Grant-Kels JM. Ethical Considerations of Cosmetic GLP-1 Receptor Agonist Prescribing in Dermatology. Clin Dermatol. 2026[...]

Epidermotropic Metastatic Prostate Adenocarcinoma With Florid Squamous Transformation/Differentiation and Associated Acantholysis. An Unusual Clinicopathologic Entity

Hoffman SJ, Sadrolashrafi K, Mobini N. Epidermotropic Metastatic Prostate Adenocarcinoma With Florid Squamous Transformation/Differentiation and Associated Acantholysis. An Unusual Clinicopathologic Entity. Case Rep Dermatol Med.[...]